English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Elderly patients with acute myeloid leukaemia frequently cannot undergo intensive chemotherapy due to comorbidities. We report a retrospective case series of elderly patients with AML treated with low dose cytarabine induction. Eleven patients with at least 25% of bone marrow blasts expressing c-kit received Imatinib post-induction therapy, 7 patients entered as controls. Haematologic responses were only slightly better in the Imatinib cohort. No correlation of the response to Imatinib with c-kit expression was noted. Partly due to two early deaths in the control cohort, survival was longer in the Imatinib cohort. Imatinib post-induction therapy after cytarabine induction is feasible in elderly patients with AML not eligible for standard induction but responders to Imatinib have only limited benefit from this low-toxic therapy while no predictive response markers could be found.

Cytarabine Induction Followed by Imatinib Post-Induction Therapy in Patients with Acute Myeloid Leukaemia - Limited Effects in a Case Series